Rachel Chua
Obstetrics & Gynecology · Lake Charles, LANPI 1871573030
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 30.2% of the total. Reporting peaked in 2019 at $666 and has fallen 97.7% since, to $16 in 2024.
Across 124 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$675
- Pfizer$228
- Takeda Pharmaceuticals U.S.A., Inc.$203
- Avion Pharmaceuticals$133
- Evofem Biosciences, Inc.$116
- Currax Pharmaceuticals LLC$106
- plus $776 from 21 others
What the payments were for
- Food & beverage$2,16697%
- Education$703%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 33 | $675 |
| Pfizer | 12 | $228 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $203 |
| Avion Pharmaceuticals | 9 | $133 |
| Evofem Biosciences, Inc. | 6 | $116 |
| Currax Pharmaceuticals LLC | 7 | $106 |
| Mayne Pharma Commercial LLC | 3 | $83 |
| Astellas Pharma US Inc | 5 | $79 |
| AMAG Pharmaceuticals, Inc. | 4 | $70 |
| Duchesnay USA Incorporated | 3 | $65 |
| Vivus LLC | 3 | $51 |
| Myovant Sciences Inc. | 2 | $46 |
| Therapeuticsmd, Inc. | 3 | $44 |
| Novo Nordisk | 3 | $42 |
| Hologic Sales And Service, LLC | 3 | $36 |
| Lupin Inc. | 2 | $32 |
| Amgen | 2 | $31 |
| Exeltis, USA Inc. | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $26 |
| Agile Therapeutics, Inc. | 1 | $25 |
| Coloplast | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Organon | 2 | $17 |
| Merck | 1 | $16 |
| Scynexis, Inc. | 1 | $13 |
| Millicent US Inc | 1 | $12 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orilissa$102
How this compares
$2,236 in reported general payments places this provider in the 70th percentile of 608 obstetrics & gynecology providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Paliperidone ErPaliperidone | 11 | $1,983 |
| Fluoxetine Hcl | 11 | $60 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Lake Charles
- Joseph SemienLake Charles$11K
- Alice BabstLake Charles$8K
- James BrownLake Charles$6K
- Veronica GillispieNew Orleans$117K
- Rachel Bezdekla Place$105K
- Earl PeeperNew Orleans$95K
- Thomas PayneBaton Rouge$84K
- Catherine VanderloosShreveport$55K
- George MorrisNew Orleans$34K
- Russell PhelpsLafayette$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.